Form 4: Axsome CEO Exercises, Sells Shares Under 10b5-1 Plan

Axsome Therapeutics CEO Herriot Tabuteau exercised expiring stock options and subsequently sold the acquired common stock shares under a pre-approved 10b5-1 plan.

Summary

• Herriot Tabuteau, CEO, Director, and 10% Owner of Axsome Therapeutics, Inc. (AXSM), executed a transaction involving the exercise of stock options and the subsequent sale of common stock.
• On February 2, 2026, Mr. Tabuteau acquired 32,410 shares of common stock at an exercise price of $8.02 per share.
• Immediately following the exercise, 32,410 shares of common stock were sold at a weighted average price of $185.6 per share, with individual sale prices ranging from $183.85 to $186.89.
• The exercise was necessary as the stock options had reached their 10-year expiration date.
• Both the exercise and sale were conducted pursuant to a pre-approved Rule 10b5-1 trading plan, which has now been completed.
• Following these transactions, Mr. Tabuteau directly holds 7,229 shares of common stock and indirectly holds 7,344,500 shares through an entity where he has voting and dispositive power.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, pre-planned insider transaction for liquidity and tax purposes, especially given the expiring options, and not necessarily indicative of a change in management's long-term view of the company's prospects.

Positives

• The transaction allowed the CEO to realize value from long-held stock options, indicating a successful vesting and appreciation of the company's stock over time.
• The transaction was executed under a pre-approved 10b5-1 plan, which demonstrates a structured and compliant approach to insider trading, reducing concerns about opportunistic selling.

Negatives

• The sale of shares by a key insider, even if pre-planned, can sometimes be perceived negatively by the market, potentially leading to short-term speculative pressure.

Future Outlook

This Form 4 filing does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The exercise of stock options was necessary due to their attainment of a 10-year expiration date.
• The transaction was executed pursuant to a pre-approved 10b5-1 plan, which has now been completed.
• The sale represents the subsequent disposition of shares acquired from the aforementioned option exercise.
• The sale price was a weighted average of transactions ranging from $183.85 to $186.89.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the exercise of expiring options and subsequent sales under a 10b5-1 plan, are a common and routine aspect of executive compensation and personal financial planning within the biotechnology and pharmaceutical industries. Such transactions are generally not indicative of a change in the company's operational outlook.

Related Party Transactions

• The reported transaction involves the CEO, a key insider, exercising stock options and selling shares of the company, which is a standard related party transaction for executive compensation.

Stakeholder Impact

• Shareholders may interpret the insider sale, but the pre-planned nature and the explanation of expiring options typically mitigate significant negative sentiment, suggesting it's for personal financial management rather than a lack of confidence in the company.

Key Dates

Recommendation

The transaction is a routine exercise of expiring options and subsequent sale under a 10b5-1 plan, which is common for executive compensation and liquidity. It does not signal a change in the company's fundamental outlook or management's confidence, thus a 'hold' recommendation is appropriate as it doesn't provide new information to alter an investment thesis.

Keywords

Axsome Therapeutics, AXSM, Herriot Tabuteau, Insider Transaction, Form 4, Stock Options, 10b5-1 Plan, CEO, Share Sale, Equity